Crypto currency

Pfizer Stock Forecast: Is It a Great Stock to Buy?

Investors have been eyeing Pfizer stocks ever since the company began shipments and became part of a mass vaccination program. Some puzzled by the market’s treatment of Pfizer, having expected the prices to skyrocket. So far, the shares have had a slow-and-steady status rather than spectacular surges.

Still, the company’s future outlook seems bright, making investors wonder whether they should jump in right now. Will Pfizer’s stock go up? Find out in this Pfizer stock price forecast!

The article covers the following subjects:

About the Pfizer Stock

Pfizer (NASDAQ: PFE) traces its origins to 1849, but it finally became a publicly-traded company in 1942, nearly a century after its founding. The $5.9 million IPO was one of the largest of that year, with shares valued at a price of $24.75 apiece. On the very first day, the company reached the market cap of $12.4 million.

At the time of its incorporation, the chemical enterprise was valued at $2 million. Today, the market cap has reached $215 billion, and it’s still one of the largest manufacturers and distributors of pharmaceuticals, agricultural and animal health products, pharmaceutical chemicals, nutritional products, and items for personal, household, and industrial use.

Currently, Pfizer is a component of the following U.S. stock market indices:

Main Factors That Drive Pfizer (PFE) in 2021 & In the Future

There is no clean equation that tells us exactly where the Pfizer stock price will go, or any stock price, for that matter. That said, we can pinpoint a few things about the forces that move PFE stock.

Everything Vaccine-Related

An 11-figure revenue outlook in 2021 is not far-fetched. Although, it depends on how quickly Pfizer can produce and distribute its COVID-19 vaccine. Plus, there are many indirect factors that may change the Pfizer stock forecast:

  • Long-term safety profile of COVID-19 vaccines;

  • Duration of immunity;

  • Effectiveness compared to the Moderna and other vaccines, especially if Pfizer’s vaccine works better;

  • Risk of variants that can evade vaccine-induced immunity;

  • Untested COVID-19 vaccine regimens.

Research and Development Potential

Pfizer keeps its pipeline of experimental first products and early commercial-stage drugs full. This is a crucial fundamental factor in the PEE stock prediction. In the last few months alone, the company made many exciting announcements, including:

  • Extension of review of Abrocitinib’s new application for the treatment of moderate to severe atopic dermatitis;

  • Application for Tanezumab as a treatment of osteoarthritis pain;

  • Initiation of phase 2 study for a Lyme disease vaccine candidate;

  • Pivotal Phase 2 MagnetisMM-3 trial of BCMA-CD3 bispecific antibody Elranatamab (PF-06863135) in multiple myeloma.

All of these combined make a compelling argument in favor of projected growth.

Cash Flows

After spinning off assets from its Upjohn unit into Viatris, Pfizer expects cash flow from its slimmed-down operations to reach at least $10 billion in 2021. This will give them more chances to invest in potential new sources of revenue.

Pfizer’s stockholders automatically receive distributed shares of the Viatris stock, but Pfizer is doing great even without big cash injections from Viatris. More importantly, the sales from its COVID-19 vaccine are not the only important contributor to the total revenue. So, the situation with cash flow and earnings seems solid.

Manufacturing Capacity

Pfizer’s vaccine is limited by the manufacturing capacity of the company and its partner, BioNTech SE. The company stated that it would scale up production in response to strong demand and increased revenue for the quarter. BioNTech added new manufacturing lines at the Lonza facility, located in Visp, Switzerland, and greenlighted other changes to the manufacturing processes.

Pfizer Index Inclusion

There is a phenomenon called the index inclusion effect. It implies that after being included in a stock index, the increased demand for the stock from index investors may increase its value. So, if other indices like the ones we mentioned earlier add the company to the list, it will be reflected in the Pfizer share price prediction.

Pfizer Price in 2021: Forecasts From Experts

Below are five projections on the Pfizer stock future from prominent analysts and firms.

Geoffrey Porges, SVB Leerink

Geoffrey Porges recently shared his Pfizer stock price forecast for 2021, where he maintained his “Hold” rating and lowered his price target from $44 to $40. This was a reaction to the news that the experimental pain medication developed by Pfizer and Eli Lilly may be less likely to gain approval.

Elmar Kraus, DZ Bank

Elmar Kraus sees growth potential as he raised his rating from “Buy” to “Strong Buy,” setting the PFE price target at $41. This is a projected 6.30% upside from the current price at the time of writing.

Vamil Divan, Mizuho

The PFE stock forecast from Vamil Divan has both good and bad price projections. On the one hand, he maintains his “Strong Buy” rating, and on the other hand, he lowered the price target from $44 to $42.

The Goldman Sachs Group

Pfizer has been assigned a $41.00 price objective by stock analysts at The Goldman Sachs Group. And the firm currently doesn’t see much growth, having a “Neutral” rating on the biopharmaceutical company’s stock.

Berenberg Bank

The mention in our analyst recommendations is Berenberg Bank. They reiterated a “Neutral” rating while also issuing a $38.00 price target on shares of Pfizer in their research note.

Technical Analysis of the PFE Price

In addition to the Pfizer share forecast, you might also be interested in learning about stock analysis. It studies technical signals derived from share price changes in addition to the price movements. Take a look at the summary for Pfizer Inc that is based on the most popular technical analysis indicators for the 1-hour timeframe to see whether you should buy or sell.

Source: Trading View

Oscillators:

  • Relative Strength Index (14) – 81.45 — Sell

  • Stochastic %K (14, 3, 3) – 90.49 — Sell

  • Awesome Oscillator – 1.04 — Buy

  • Momentum (10) – 0.46 — Sell

  • MACD Level (12, 26) – 0.46 — Buy

Moving Averages:

  • Exponential Moving Average (50) – 37.55 — Buy

  • Simple Moving Average (50) – 37.33 — Buy

  • Exponential Moving Average (100) – 36.95 — Buy

  • Simple Moving Average (100) – 36.77 — Buy

The chart above features the crossover of EMA-10 and MA-25, signaling a bullish trend. Based on the technicals, as well as the fact that Pfizer is scaling up manufacturing and increasing sales, the long-term price target can be set at 55 USD.

PFE Price Prediction for 2022

How much can Pfizer stock grow this year, and where will 2022 pick it up? Gov Capital shared their Pfizer stock price forecast for 2022. According to this source, the stock will lay low at the beginning of next year and make a big leap in mid-spring.

Month

Average Price

Minimum Price

Maximum Price

January 2022

44.405

37.74425

51.06575

February 2022

43.798

37.2283

50.3677

March 2022

42.302

35.9567

48.6473

April 2022

43.003

36.55255

49.45345

May 2022

72.054

61.2459

82.8621

June 2022

72.185

61.35725

83.01275

July 2022

73.066

62.1061

84.0259

August 2022

73.389

62.38065

84.39735

September 2022

72.316

61.4686

83.1634

October 2022

73.057

62.09845

84.01555

November 2022

74.390

63.2315

85.5485

December 2022

77.147

65.57495

88.71905

The drastic surge in PFE stocks’ value in the spring may be caused by the company’s increased capacity (3 billion doses of the vaccine) and authorization for vaccination of younger kids (6 months to 11 years).

Pfizer Price Forecast for 2023

Gov Capital’s PFE forecast for 2023 is full of surprises – future prices might be falling in the first few months and an explosive increase (possibly caused by an expected spike in sales).

Month

Average Price

Minimum Price

Maximum Price

January 2023

76.264

64.8244

87.7036

February 2023

75.754

64.3909

87.1171

March 2023

73.546

62.5141

84.5779

April 2023

74.637

63.44145

85.83255

May 2023

114.109

96.99265

131.22535

June 2023

113.843

96.76655

130.91945

July 2023

114.422

97.2587

131.5853

August 2023

116.733

99.22305

134.24295

September 2023

116.220

98.787

133.653

October 2023

117.124

99.5554

134.6926

November 2023

117.932

100.2422

135.6218

December 2023

121.611

103.36935

139.85265

Again, the source expects a sudden rise in PFE’s value. This may be explained by the EU buying more doses of the Pfizer-BioNTech in 2023 — 1.8 billion.

What Will Pfizer Stock Be Worth in 2025-2030?

This Pfizer stock forecast for 2025 is provided by Digital Coin Price. Contrasting it to the Gov Capital’s prediction for 2023, the values provided for 2025 are nothing but a natural progression (as long as all developments go according to plan).

Month

Average Price

Change

Jan 2025

109.34 

178.7%

Feb 2025

121.09 

208.64%

Mar 2025

119.62 

204.9%

Apr 2025

121.14 

208.76%

May 2025

117.71 

200.02%

Jun 2025

115.79 

195.13%

Jul 2025

122.72 

212.8%

Aug 2025

121.6 

209.93 %

Sep 2025

122.33 

211.81%

Oct 2025

121.38 

209.39%

Nov 2025

105.72 

169.46%

Dec 2025

115.66 

194.81%

We can also analyze the possible change from 2025 to 2030. For instance, AI Pickup predicts a realistic future growth of around 100%-150%.

Year

Average Value

Minimum Value

Maximum Value

Change from closing price on April 16, 2021

2025

$77.88

$73.17

$83.12

101.92%

2030

$83.02

$72.36

$91.09

115.23%

Kind reminder: Pfizer stock projections for 2030 is only an estimated assumption. With forecasts so far into the future, accuracy is limited. Even the Pfizer stock 5-year forecast should be taken with a degree of skepticism. That’s why conservative investors may have a preference for indices like S&P 500 rather than try to pick the stock performance winners.

Pfizer’s Stock Price Changes Over Time

Having checked the Pfizer predictions, let’s take a look back to gain some perspective. Below is the timeline of some of the most notable events (in recent price history):

  • October 2016: A public health emergency Zika – stock price at $28.

  • 2017: Lackluster financial results – $31-$34.

  • February 2018: Millions paid to resolve co-pay allegations – close to $32.

  • November 2018: Announcement of plans to raise the list prices of 10% of its portfolio – $43

  • July-August 2019: Poor decision to spin off its generic drug business – from $40 to $32. 

  • March 2020: WHO declares COVID-19 a Pandemic – the stock quote fell to $27.

  • May-June 2020: Safety study of four different COVID-19 vaccine variations – from $36 down to $30 and back to $36.

  • July 2020: Two vaccine candidates winning regulatory approval from the FDA – a rise to $37.5.

  • November: Pfizer and BioNTech announce the vaccine’s success.

  • December of the same year: The FDA issued the first emergency use authorization (EUA) for the vaccine – $42.5.

  • February 2021: Unfulfilled earnings expectations – $33. 

  • March-April 2021: Operation Warp Speed and plans to increase output – $38.

Is Pfizer a Good Long-Term Investment?

Pfizer doesn’t draw long-term investors by quick pops and drops but rather solid stock performance over the years versus months or even days. Overall, the Pfizer share forecast confirms that the company is a top pick for those seeking profit from a pharma giant. 

This Pfizer stock outlook by Coin Price Forecast is adamant that Pfizer’s stock is a good one.

Year

Mid-Year Results

End-of-Year Results

Tod/End,%

2021

$42.32

$42.94

+11%

2022

$49.32

$52.57

+36%

2023

$59.36

$63.19

+64%

2024

$64.09

$69.58

+80%

2025

$74.01

$76.84

+99%

2026

$77.23

$77.34

+101%

2027

$81.18

$82.85

+115%

2028

$84.59

$86.41

+124%

2029

$88.31

$90.29

+134%

2030

$92.37

$94.54

+145%

The right broker can open up speculation and investment opportunities, but the wrong one can limit your options and push up your costs. Make the right choice by creating a Liteforex demo account today. 15 years on the market, numerous trading instruments, personal managers, and a lot more.

Pfizer Stock Forecast FAQ

The content of this article is intended to be used for informational and educational purposes only. We are not an investment advisor. Information featured in the article was gathered from various resources that may not be accurate. Before investing, make sure you understand the risk that if the market moves against you, you may sustain a loss.

Price chart of PFE in real time mode

The content of this article reflects the author’s opinion and does not necessarily reflect the official position of LiteForex. The material published on this page is provided for informational purposes only and should not be considered as the provision of investment advice for the purposes of Directive 2004/39/EC.

Rate this article:

{{value}} ( {{count}} {{title}} )


Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button